Expression of CD133 and other putative stem cell markers in uveal melanoma

Melanoma Research

Volumn 21, Issue 5, 2011, Pages 405-416

  Thill, Michelle ^a   Berna, Marc Jean ^b   Grierson, Rebecca ^a   Reinhart, Inna ^a   Voelkel, Tobias ^d   Piechaczek, Christoph ^d   Galambos, Peter ^a   Jager, Martine J ^e   Richard, Gisbert ^a   Lange, Claudia ^c   Gehling, Ursula M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Internal Medicine ^*  (Germany)

^c Clinic for Stem Cell Transplantation   (Germany)

^d MILTENYI BIOTEC GMBH   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cancer stem cell; CD133; uveal melanoma

Indexed keywords

ABCB5 PROTEIN; CD133 ANTIGEN; CD68 ANTIGEN; CELL MARKER; CHEMOKINE RECEPTOR CXCR4; HERMES ANTIGEN; MESSENGER RNA; MUSASHI PROTEIN; NESTIN; PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CHOROID; CILIARY BODY; CONTROLLED STUDY; EXON; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; IMMUNOHISTOCHEMISTRY; IRIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; MALE; MELANOMA; MICE; MIDDLE AGED; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PEPTIDES; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 80052682209     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328348db10     Document Type: Article

References (72)

1. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114:2309-2315.
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:956-961. (Pubitemid 36560496)
3. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:962-965. (Pubitemid 36560497)
4. Al-Jamal RT, Makitie T, Kivela T. Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest Ophthalmol Vis Sci 2003; 44:2381-2389. (Pubitemid 36618392)
5. Folberg R, Maniotis AJ. Vasculogenic mimicry. APMIS 2004; 112:508-525. (Pubitemid 39626057)
6. Seregard S, Spangberg B, Juul C, Oskarsson M. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology 1998; 105:485-491. (Pubitemid 28125103)
7. Ly L, Odish O, De Wolff-Rouendaal D, Missotten G, Luyten G, Jager M. Intravascular presence of tumor cells as prognostic parameter in uveal melanoma: a 35-year survey. Invest Ophthalmol Vis Sci 2009; 51:658-665.
8. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:1414-1421. (Pubitemid 32520728)
9. Maat W, Ly LV, Jordanova ES, De Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:505-510.
10. Horsman DE, Sroka H, Rootman J, White VA. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet Cytogenet 1990; 45:249-253. (Pubitemid 20129149)
11. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-1225. (Pubitemid 26131850)
12. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64:7205-7209. (Pubitemid 39372052)
13. Zuidervaart W, Van der Velden PA, Hurks MH, Van Nieuwpoort FA, Out-Luiting CJ, Singh AD, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer 2003; 89:1914-1919. (Pubitemid 37533270)
14. Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 2008; 18:191-200. (Pubitemid 351684664)
15. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-5828. (Pubitemid 37187480)
16. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-110. (Pubitemid 46067310)
17. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13:153-166. (Pubitemid 351163165)
18. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27:2875-2883.
19. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature 2008; 451:345-349.
20. Giebel B, Corbeil D, Beckmann J, Hohn J, Freund D, Giesen K, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004; 104:2332-2338. (Pubitemid 39331830)
21. Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 1997; 94:12425-12430. (Pubitemid 27492544)
22. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2:82-91. (Pubitemid 32219860)
23. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90:5013-5021. (Pubitemid 28007218)
24. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90:5002-5012. (Pubitemid 28007217)
25. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95:3106-3112. (Pubitemid 30321161)
26. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000; 97:14720-14725. (Pubitemid 32016642)
27. Sawamoto K, Nakao N, Kakishita K, Ogawa Y, Toyama Y, Yamamoto A, et al. Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci 2001; 21:3895-3903. (Pubitemid 32466481)
28. Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, et al. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 2005; 8:723-729. (Pubitemid 43085837)
29. Belicchi M, Pisati F, Lopa R, Porretti L, Fortunato F, Sironi M, et al. Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res 2004; 77:475-486. (Pubitemid 39006999)
30. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23:7267-7273. (Pubitemid 39382160)
31. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-115. (Pubitemid 46067311)
32. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007; 43:935-946. (Pubitemid 46366698)
33. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5:67.
34. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007; 20:102-107. (Pubitemid 44967955)
35. Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K, et al. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer 2008; 8:300.
36. Fargeas CA, Huttner WB, Corbeil D. Nomenclature of prominin-1 (CD133) splice variants: an update. Tissue Antigens 2007; 69:602-606. (Pubitemid 46733679)
37. Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB, Corbeil D. Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci 2004; 117:4301-4311. (Pubitemid 39328316)
38. Yu Y, Flint A, Dvorin EL, Bischoff J. AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 2002; 277:20711-20716. (Pubitemid 34967375)
39. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, Bridges RJ, et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000; 9:27-34. (Pubitemid 30145285)
40. Ye J, Song YS, Kang SH, Yao K, Kim JC. Involvement of bone marrow-derived stem and progenitor cells in the pathogenesis of pterygium. Eye 2004; 18:839-843. (Pubitemid 39173418)
41. Song YS, Ryu YH, Choi SR, Kim JC. The involvement of adult stem cells originated from bone marrow in the pathogenesis of pterygia. Yonsei Med J 2005; 46:687-692. (Pubitemid 41804745)
42. Chan CC, Chew EY, Shen D, Hackett J, Zhuang Z. Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis 2005; 11:697-704. (Pubitemid 41410204)
43. Sheridan CM, Rice D, Hiscott PS, Wong D, Kent DL. The presence of AC133-positive cells suggests a possible role of endothelial progenitor cells in the formation of choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47:1642-1645. (Pubitemid 46780777)
44. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118:2111-2120. (Pubitemid 351872330)
45. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 2008; 118:2021-2024. (Pubitemid 351872322)
46. Meng X, Li M, Wang X, Wang Y, Ma D. Both CD133+ and CD133-subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 2009; 100:1040-1046.
47. De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 1995; 62:155-161.
48. Soulieres D, Rousseau A, Tardif M, Larochelle M, Tremblay M, Vaillancourt L, et al. The radiosensitivity of uveal melanoma cells and the cell survival curve. Graefe's Arch Clin Exp Ophthalmol 1995; 233:85-89.
49. Tardif M, Coulombe J, Soulieres D, Rousseau AP, Pelletier G. Gangliosides in human uveal melanoma metastatic process. Int J Cancer 1996; 68:97-101. (Pubitemid 26354585)
50. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis 1997; 15:509-518. (Pubitemid 27323900)
51. Luyten GP, Naus NC, Mooy CM, Hagemeijer A, Kan-Mitchell J, Van Drunen E, et al. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer 1996; 66:380-387. (Pubitemid 26163610)
52. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer 1997; 73:470-478. (Pubitemid 28005307)
53. Larouche N, Larouche K, Beliveau A, Leclerc S, Salesse C, Pelletier G, et al. Transcriptional regulation of the alpha 4 integrin subunit gene in the metastatic spread of uveal melanoma. Anticancer Res 1998; 18 (5A):3539-3547. (Pubitemid 28546488)
54. Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, Boitano M, et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 2009; 21:793-801.
55. Jaksch M, Munera J, Bajpai R,Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008; 68:7882-7886.
56. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65:4320-4333. (Pubitemid 40775671)
57. Gedye C, Quirk J, Browning J, Svobodova S, John T, Sluka P, et al. Cancer/testis antigens can be immunological targets in clonogenic CD133 + melanoma cells. Cancer Immunol Immunother 2009; 58:1635-1646.
58. Zuk PA. The intracellular distribution of the ES cell totipotent markers OCT4 and Sox2 in adult stem cells differs dramatically according to commercial antibody used. J Cell Biochem 2009; 106:867-877.
59. Piras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C, et al. The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep 2010; 23:17-24.
60. Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, et al. Higher percentage of CD133 + cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009; 7:56.
61. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14:123-129. (Pubitemid 351377986)
62. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133 + tumour cells and clinical outcome in rectal cancer. Histopathology 2009; 55:284-293.
63. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008; 62:1212-1218. (Pubitemid 351977611)
64. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99:1285-1289.
65. Tong QS, Zheng LD, Tang ST, Ruan QL, Liu Y, Li SW, et al. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 2008; 4:58-62. (Pubitemid 351234092)
66. Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells 2003; 21:506-508. (Pubitemid 36793492)
67. Fargeas CA, Florek M, Huttner WB, Corbeil D. Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. J Biol Chem 2003; 278:8586-8596. (Pubitemid 36800613)
68. Coles BL, Angenieux B, Inoue T, Del Rio-Tsonis K, Spence JR, McInnes RR, et al. Facile isolation and the characterization of human retinal stem cells. Proc Natl Acad Sci USA 2004; 101:15772-15777. (Pubitemid 39473563)
69. Mayer EJ, Carter DA, Ren Y, Hughes EH, Rice CM, Halfpenny CA, et al. Neural progenitor cells from postmortem adult human retina. Br J Ophthalmol 2005; 89:102-106. (Pubitemid 40040248)
70. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000; 275:5512-5520. (Pubitemid 30115186)
71. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005; 319:15-26. (Pubitemid 40104635)
72. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008; 26:3008-3017.